← Human Trials & Peer-Reviewed Studies
Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.
Plain-language guide to PMID 2180981 (1990): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 9 patients.
Key Facts
- PMID
- 2180981
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1990
- Study type
- Randomized Controlled Trial
- Authors
- Johansen JS et al. (7 authors)
- DOI
- 10.1210/jcem-70-4-916
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Both deficiency and excess of GH are related to disturbances in calcium metabolism.
Bone Gla protein (BGP) is the only specific marker of bone turnover identified in peripheral blood.
Who Took Part
According to the abstract, 9 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.
What Was Measured
PubMed files the paper under topics including Acromegaly, Biomarkers, Bone Resorption, Growth Hormone, Osteocalcin, Randomized Controlled Trials as Topic and Recombinant Proteins.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 9 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1990 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.